Sugi Predict

Sugi Predict / Compounds / SCHEMBL4726064

SCHEMBL4726064

SCHEMBL4726064

CC(C)(C)OC(=O)NC1(CO)CCNC1

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ P2RX7 Q99572 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ KMT2A Q03164 2/20 0.33
▸ CTSL P07711 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ APLNR P35414 1/20 0.32
▸ MAOA P21397 1/20 0.31
▸ MAOB P27338 1/20 0.31
▸ PPIA P62937 1/20 0.30
▸ CA1 P00915 1/20 0.30
▸ CA2 P00918 1/20 0.30
▸ CA7 P43166 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ CTSK P43235 1/20 0.30
▸ GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13738955 1.00 P2RX7 (0.34) P2RX7TDP1KMT2ACTSLMEN1
SCHEMBL22481442 0.91 P2RX7 (0.38) P2RX7TDP1KMT2ACTSLMEN1
SCHEMBL17606749 0.91 TDP1 (0.36) P2RX7TDP1KMT2ACTSLMEN1
SCHEMBL16993451 0.88 TDP1 (0.36) P2RX7TDP1KMT2ACTSLMEN1
SCHEMBL18530347 0.88 TDP1 (0.36) P2RX7TDP1KMT2ACTSLMEN1
SCHEMBL13738101 0.88 P2RX7 (0.34) P2RX7TDP1KMT2ACTSLMEN1
SCHEMBL3942864 0.88 P2RX7 (0.34) P2RX7TDP1KMT2ACTSLMEN1
SCHEMBL20296850 0.87 MEN1 (0.39) P2RX7TDP1KMT2ACTSLMEN1
Acetic Acid SCHEMBL28797854 0.87 P2RX7 (0.34) P2RX7TDP1KMT2ACTSLMEN1
SCHEMBL8568717 0.87 APLNR (0.34) P2RX7TDP1KMT2ACTSLMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179059-A1 ANTICANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-06-05 — — US disclosed
US-12162870-B2 Anticancer compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-10 — — US disclosed
US-12157746-B2 Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease HOFFMANN-LA ROCHE INC. (US) 2024-12-03 — — US disclosed
US-12037345-B2 Heterobicyclic compounds for inhibiting the activity of SHP2 TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-16 — — US disclosed
CN-117794525-A Anticancer compounds 加利福尼亚大学董事会 2024-03-29 — — CN disclosed
EP-3802539-B1 TETRAHYDRO-1H-PYRAZINO[2,1-A]ISOINDOLYLQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN LA ROCHE (CH) 2023-09-20 — — EP disclosed
EP-3654968-B1 METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-08-16 — — EP disclosed
EP-3752498-B1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2023-06-28 — — EP disclosed
US-11608335-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-03-21 — — US disclosed
US-20230025178-A1 ANTICANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-01-26 — — US disclosed
US-9169261-B2 CXCR7 antagonists CHEMOCENTRYX, INC. (US) 2015-10-27 — — US disclosed
US-8889704-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2014-11-18 — — US disclosed
US-20140154179-A1 CXCR7 ANTAGONISTS CHEMOCENTRYX, INC. (US) 2014-06-05 — — US disclosed
WO-2014085490-A1 CXCR7 ANTAGONISTS CHEMOCENTRYX, INC. (US) 2014-06-05 — — WO disclosed
US-20140005213-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-01-02 — — US disclosed
EP-2678329-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS Array Biopharma, Inc. (US) 2014-01-01 — — EP disclosed
CN-103492377-A Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC 2014-01-01 — — CN disclosed
WO-2012154274-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2012-11-15 — — WO disclosed
US-20080051419-A1 AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. 2008-02-28 — — US disclosed
WO-2008012635-A2 AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2008-01-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179059-A1 ANTICANCER COMPOUNDS BET1, BRD4, BICRA P2RX7 4582/4885TDP1 2403/4885KMT2A 1062/4885
US-20230025178-A1 ANTICANCER COMPOUNDS BET1, BRD4, BICRA P2RX7 4582/4885TDP1 2403/4885KMT2A 1062/4885
US-20140005213-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 P2RX7 2269/4885TDP1 424/4885KMT2A 1239/4885
US-11608335-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 P2RX7 1037/4885TDP1 2824/4885KMT2A 4607/4885
US-12157746-B2 Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease HLA-DRB1, SSB, REN P2RX7 949/4885TDP1 1647/4885KMT2A 811/4885
US-20140154179-A1 CXCR7 ANTAGONISTS CXCR1, CXCR5, CCR7 P2RX7 28/4885TDP1 4641/4885KMT2A 4596/4885
US-20080051419-A1 AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS CCNY, CCND2, CCND1 P2RX7 3462/4885TDP1 1208/4885KMT2A 283/4885
US-12162870-B2 Anticancer compounds BET1, BRD4, BICRA P2RX7 4582/4885TDP1 2403/4885KMT2A 1062/4885
US-12037345-B2 Heterobicyclic compounds for inhibiting the activity of SHP2 PTPN1, PTPN9, PTPN7 P2RX7 570/4885TDP1 3032/4885KMT2A 1327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.